NASDAQ:CDAK Codiak BioSciences (CDAK) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free CDAK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0016▼$0.001650-Day Range N/A52-Week Range$0.05▼$6.98VolumeN/AAverage Volume1.37 million shsMarket Capitalization$58,928.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Codiak BioSciences alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Codiak BioSciences Stock (NASDAQ:CDAK)Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> CDAK Stock News HeadlinesJanuary 13, 2024 | morningstar.comMarvel Biosciences Corp MRVLMay 19, 2023 | finance.yahoo.comMariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial OfficerApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 15, 2023 | reuters.comCDAK.OApril 2, 2023 | benzinga.comHow Does Codiak BioSciences Inc (CDAK) Stock Rank on Wall Street Friday?March 27, 2023 | finance.yahoo.comCodiak BioSciences Files For Chapter 11 BankruptcyMarch 27, 2023 | marketwatch.comCodiak BioSciences Shares Hit 52-Week Low After Bankruptcy FilingMarch 27, 2023 | bizjournals.comStruggling MD Anderson spinout files for bankruptcy protectionApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 27, 2023 | finanznachrichten.deCodiak BioSciences, Inc.: Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 ProcessMarch 27, 2023 | benzinga.comCodiak BioSciences shares are trading lower after the company voluntarily filed for protection under Chapter 11 bankruptcy.March 27, 2023 | reuters.comCOVID vaccine developer Codiak files for US bankruptcy protectionMarch 27, 2023 | msn.comCodiak Bio Tumbles on Bankruptcy FilingMarch 27, 2023 | markets.businessinsider.comCodiak BioSciences Voluntarily Files For Bankruptcy ProtectionMarch 27, 2023 | finance.yahoo.comCodiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 ProcessMarch 22, 2023 | seekingalpha.comCDAK Codiak BioSciences, Inc.March 3, 2023 | msn.comLaurion Capital Management Now Owns 9.60% of Codiak BioSciences (CDAK)February 21, 2023 | bizjournals.comBlood disorder startup Hemab Therapeutics raises $135MNovember 28, 2022 | finance.yahoo.comCodiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx ConferenceNovember 10, 2022 | finance.yahoo.comCodiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingNovember 9, 2022 | finance.yahoo.comCodiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 4, 2022 | finance.yahoo.comCodiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue EstimatesNovember 3, 2022 | technews.tmcnet.comCodiak BioSciences Reports Third Quarter 2022 Financial Results and Operational ProgressNovember 3, 2022 | finance.yahoo.comCodiak BioSciences Reports Third Quarter 2022 Financial Results and Operational ProgressOctober 19, 2022 | finance.yahoo.comAll You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong BuyOctober 12, 2022 | finance.yahoo.comCodiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related SarbecovirusesOctober 6, 2022 | finance.yahoo.comBiohaven (BHVN) Stock Up on Spin-Off Transaction FinalizationSee More Headlines Receive CDAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDAK CUSIPN/A CIK1659352 Webwww.codiakbio.com Phone617-949-4100FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-51.13% Pretax Margin-51.13% Return on Equity-109.51% Return on Assets-34.44% Debt Debt-to-Equity Ratio0.66 Current Ratio4.24 Quick Ratio4.24 Sales & Book Value Annual Sales$33.57 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.00Miscellaneous Outstanding Shares36,830,000Free Float33,810,000Market Cap$58,928.00 OptionableNot Optionable Beta3.71 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Douglas Edward Williams Ph.D. (Age 64)Pres, CEO & Director Comp: $970.77kMs. Linda Cathavina Bain CPA (Age 52)CFO & Treasurer Comp: $602.54kDr. Sriram Sathyanarayanan Ph.D. (Age 50)Chief Scientific Officer Comp: $502.17kDr. Konstantin Konstantinov Ph.D. (Age 64)Chief Technology Officer Mr. Christopher J. M. TaylorVP of Investor Relations & Corp. CommunicationsMs. Yalonda Howze (Age 50)Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. Ms. Nicole Barna (Age 48)Sr. VP of HR Dr. David J. Mauro M.D. (Age 57)Ph.D., Chief Medical Officer Dr. Benny Sorensen M.D. (Age 48)Ph.D., Member of Scientific Advisory Board & Consultant More ExecutivesKey CompetitorsIgnyte AcquisitionNASDAQ:IGNYPeak BioNASDAQ:PKBOScopus BioPharmaNASDAQ:SCPSStatera BiopharmaNASDAQ:STABBruush Oral CareNASDAQ:BRSHView All Competitors CDAK Stock Analysis - Frequently Asked Questions How were Codiak BioSciences' earnings last quarter? Codiak BioSciences, Inc. (NASDAQ:CDAK) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.12. The company had revenue of $1.16 million for the quarter, compared to analysts' expectations of $2.87 million. Codiak BioSciences had a negative net margin of 51.13% and a negative trailing twelve-month return on equity of 109.51%. When did Codiak BioSciences IPO? Codiak BioSciences (CDAK) raised $82 million in an initial public offering on Wednesday, October 14th 2020. The company issued 5,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow acted as the underwriters for the IPO. This page (NASDAQ:CDAK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codiak BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
